Vectura Group PLC (VEC)

164.80
-0.20(-0.12%)
  • Volume:
    61,901
  • Bid/Ask:
    164.60/165.00
  • Day's Range:
    164.60 - 165.00

VEC Overview

Prev. Close
165
Day's Range
164.6-165
Revenue
100.9M
Open
165
52 wk Range
100-176
EPS
0.2
Volume
61,901
Market Cap
1B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
5,547,803
P/E Ratio
8.03
Beta
0.46
1-Year Change
58.77%
Shares Outstanding
609,587,190
Next Earnings Date
21 Dec 2021
What is your sentiment on Vectura Group PLC?
or
Market is currently closed. Voting is open during market hours.

Vectura Group PLC News

Vectura Group PLC Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellBuyStrong BuyStrong Buy
Technical IndicatorsBuyStrong SellBuyBuyStrong Buy
SummaryNeutralStrong SellBuyStrong BuyStrong Buy

Vectura Group PLC Company Profile

Vectura Group PLC Company Profile

Employees
500

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.

Read More
  • £958 million takeover yesterday by Carlyle Group.
    0
    • Anyone know why the share popped 13% today?
      1
      • Glaxo denied appeal.
        1
      • Glaxo denied appeal.
        1
    • https://www.gov.uk/government/news/government-invests-in-uk-developed-antibody-tests-from-uk-rapid-test-consortium
      1
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.